Most cited papers from Seattle Cancer Care Alliance
What are the most cited papers from Seattle Cancer Care Alliance?
The most cited paper from Seattle Cancer Care Alliance is "Massively parallel digital transcriptional profiling of single cells" (Grace X. Y. Zheng et al., 2017), with 8,144 citations. Next come "Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer" (8,100) and "Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer" (5,577).
Showing 50 of 59 papers. Every paper with more than 683 citations is listed.
| # | Paper | ||
|---|---|---|---|
| 1 | Massively parallel digital transcriptional profiling of single cells Grace X. Y. Zheng et al. · Nature Communications | 16 Jan 2017 | 8,144 |
| 2 | Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer Julie Renee Brahmer et al. · New England Journal of Medicine | 14 Jun 2012 | 8,100 |
| 3 | Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer Philip W. Kantoff, Celestia S. Higano, Neal D. Shore et al. · New England Journal of Medicine | 28 Jul 2010 | 5,577 |
| 4 | Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet Hartmut Döhner, Elihu H. Estey, Sergio Amadori et al. · Blood | 30 Oct 2009 | 3,422 |
| 5 | Enzalutamide in Metastatic Prostate Cancer before Chemotherapy Tomasz M. Beer et al. · New England Journal of Medicine | Jun 2014 | 3,076 |
| 6 | Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Robert John Motzer, Bernard J. Escudier, Stéphane Marie. Oudard et al. · The Lancet | 23 Jul 2008 | 3,036 |
| 7 | Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children Alexander Edward Dela Cruz Drilon et al. · New England Journal of Medicine | 21 Feb 2018 | 2,827 |
| 8 | American Cancer Society Guidelines for Breast Screening with MRI as an Adjunct to Mammography Debbie Saslow, Carla Boetes, Wylie Burke et al. · CA A Cancer Journal for Clinicians | Mar 2007 | 2,657 |
| 9 | Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer Robert Allen Burger, Mark F. Brady, Michael A. Bookman et al. · New England Journal of Medicine | 28 Dec 2011 | 2,422 |
| 10 | Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue Anand Padmanabhan, Laura S. Connelly‐Smith, Nicole A. Aqui et al. · Journal of Clinical Apheresis | Jun 2019 | 2,235 |
| 11 | Clinical Guidelines for the Use of Chronic Opioid Therapy in Chronic Noncancer Pain Roger Chou et al. · Journal of Pain | Feb 2009 | 2,216 |
| 12 | Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update Bryan J. Schneider et al. · Journal of Clinical Oncology | Nov 2021 | 2,212 |
| 13 | Head and Neck Cancer Laura Q.M. Chow · New England Journal of Medicine | 2020 | 2,145 |
| 14 | Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology Al B. Benson et al. · Journal of the National Comprehensive Cancer Network | Mar 2021 | 1,789 |
| 15 | Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology Jaffer A. Ajani et al. · Journal of the National Comprehensive Cancer Network | Feb 2022 | 1,772 |
| 16 | Epidemiology of Renal Cell Carcinoma Umberto Capitanio, Karim Bensalah, Axel Bex et al. · European Urology | 20 Sep 2018 | 1,699 |
| 17 | Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology William John Gradishar et al. · Journal of the National Comprehensive Cancer Network | Apr 2020 | 1,628 |
| 18 | Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology William John Gradishar et al. · Journal of the National Comprehensive Cancer Network | Mar 2018 | 1,621 |
| 19 | Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial Antoni Ribas et al. · The Lancet Oncology | 24 Jun 2015 | 1,581 |
| 20 | Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology James Lloyd Mohler et al. · Journal of the National Comprehensive Cancer Network | May 2019 | 1,580 |
| 21 | Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma Thomas B. Powles et al. · New England Journal of Medicine | 18 Sep 2020 | 1,526 |
| 22 | Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology David S. Ettinger et al. · Journal of the National Comprehensive Cancer Network | May 2022 | 1,453 |
| 23 | Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial Kathy S. Albain et al. · The Lancet Oncology | 12 Dec 2009 | 1,418 |
| 24 | Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study Corey Jay Langer, Shirish M. Gadgeel, Hossein Borghaei et al. · The Lancet Oncology | 12 Oct 2016 | 1,407 |
| 25 | Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology David G. Pfister et al. · Journal of the National Comprehensive Cancer Network | Jul 2020 | 1,406 |
| 26 | Age and acute myeloid leukemia Frederick R. Appelbaum, Holly M. Gundacker, David R. Head et al. · Blood | 2 Feb 2006 | 1,356 |
| 27 | Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology Margaret A. Tempero et al. · Journal of the National Comprehensive Cancer Network | Apr 2021 | 1,340 |
| 28 | Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology Margaret von Mehren et al. · Journal of the National Comprehensive Cancer Network | Jul 2022 | 1,188 |
| 29 | The global burden of women’s cancers: a grand challenge in global health Ophira Ginsburg et al. · The Lancet | Nov 2016 | 1,163 |
| 30 | Updated international consensus report on the investigation and management of primary immune thrombocytopenia Drew Provan et al. · Blood Advances | 26 Nov 2019 | 1,151 |
| 31 | Phase 3 trial of everolimus for metastatic renal cell carcinoma Robert John Motzer, Bernard J. Escudier, Stéphane Marie. Oudard et al. · Cancer | 14 Jun 2010 | 1,148 |
| 32 | Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology Mary B. Daly et al. · Journal of the National Comprehensive Cancer Network | 6 Jan 2021 | 1,130 |
| 33 | Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology Jaffer A. Ajani et al. · Journal of the National Comprehensive Cancer Network | Jul 2019 | 1,106 |
| 34 | Spatial transcriptomics at subspot resolution with BayesSpace Edward J. Zhao, Matthew R. Stone, Xing Ren et al. · Nature Biotechnology | 3 Jun 2021 | 1,101 |
| 35 | Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology Wui-Jin Koh et al. · Journal of the National Comprehensive Cancer Network | 2019 | 1,088 |
| 36 | Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology Al B. Benson et al. · Journal of the National Comprehensive Cancer Network | May 2021 | 1,068 |
| 37 | Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline Larissa A. Korde, Mark R. Somerfield, Lisa A. Carey et al. · Journal of Clinical Oncology | 28 Jan 2021 | 1,053 |
| 38 | Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology Margaret A. Tempero et al. · Journal of the National Comprehensive Cancer Network | Aug 2017 | 1,046 |
| 39 | NCCN Guidelines Insights: Colon Cancer, Version 2.2018 Al B. Benson et al. · Journal of the National Comprehensive Cancer Network | Apr 2018 | 1,045 |
| 40 | Diagnosis and Management of Multiple Myeloma Andrew J. Cowan, Damian J. Green, Mary Kwok et al. · JAMA | Feb 2022 | 1,033 |
| 41 | NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021 David S. Ettinger et al. · Journal of the National Comprehensive Cancer Network | Mar 2021 | 1,017 |
| 42 | NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 1.2020 David S. Ettinger et al. · Journal of the National Comprehensive Cancer Network | Dec 2019 | 1,009 |
| 43 | Chromatin accessibility pre-determines glucocorticoid receptor binding patterns Sam John, Peter J. Sabo, Robert E. Thurman et al. · Nature Genetics | 23 Jan 2011 | 994 |
| 44 | Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology Jaffer A. Ajani et al. · Journal of the National Comprehensive Cancer Network | Oct 2016 | 966 |
| 45 | Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet Miguel Ángel Sanz, David J. Grimwade, Martin S. Tallman et al. · Blood | 24 Sep 2008 | 960 |
| 46 | The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia Yu Liu et al. · Nature Genetics | 3 Jul 2017 | 955 |
| 47 | Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer Robert Louis Coleman et al. · New England Journal of Medicine | 28 Sep 2019 | 944 |
| 48 | Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: the AEIOU features Michelle Heath, Natalia Jaimes, Bianca D. Lemos et al. · Journal of the American Academy of Dermatology | 15 Feb 2008 | 935 |
| 49 | Distress Management, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology Michelle B. Riba et al. · Journal of the National Comprehensive Cancer Network | Oct 2019 | 892 |
| 50 | KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study Bijal Dinesh Shah et al. · The Lancet | 4 Jun 2021 | 815 |
Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.